Emmaus Life Sciences, Inc. SEC filings EMMA
Emmaus Life Sciences, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Sep 2, 2009. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 31, 2022 | Dec 8, 2022 |
| PRE 14A | Preliminary proxy statement | Oct 21, 2022 | Dec 8, 2022 |
| DEF 14A | Proxy statement | Oct 12, 2021 | Nov 23, 2021 |
| PRE 14A | Preliminary proxy statement | Sep 30, 2021 | Nov 23, 2021 |
| DEF 14A | Proxy statement | Nov 2, 2018 | Nov 26, 2018 |
| PRE 14A | Preliminary proxy statement | Oct 23, 2018 | Oct 23, 2018 |
| DEF 14A | Proxy statement | Mar 1, 2018 | Apr 4, 2018 |
| DEFA14A | Additional proxy material | Aug 15, 2017 | — |
| DEF 14A | Proxy statement | Jul 27, 2017 | Jun 5, 2017 |
| PRE 14A | Preliminary proxy statement | Apr 25, 2017 | Apr 25, 2017 |
| DEF 14A | Proxy statement | Oct 6, 2016 | Nov 1, 2016 |
| DEF 14A | Proxy statement | Oct 6, 2015 | Oct 28, 2015 |
| PRE 14A | Preliminary proxy statement | Sep 18, 2015 | Sep 17, 2015 |
| DEF 14A | Proxy statement | Apr 9, 2014 | May 13, 2014 |
| PRE 14A | Preliminary proxy statement | Mar 25, 2014 | Mar 25, 2014 |
| DEF 14A | Proxy statement | May 8, 2013 | May 23, 2013 |
| PRE 14A | Preliminary proxy statement | Apr 26, 2013 | Apr 26, 2013 |
| DEF 14A | Proxy statement | Jan 6, 2012 | Jan 27, 2012 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2011 | Dec 23, 2011 |
| DEF 14A | Proxy statement | Apr 1, 2010 | Apr 27, 2010 |
| DEFA14A | Additional proxy material | Sep 25, 2009 | — |
| DEFA14A | Additional proxy material | Sep 21, 2009 | — |
| DEFA14A | Additional proxy material | Sep 18, 2009 | — |
| DEF 14A | Proxy statement | Sep 15, 2009 | Sep 15, 2009 |
| DEFA14A | Additional proxy material | Sep 14, 2009 | — |
| DEFA14A | Additional proxy material | Sep 10, 2009 | — |
| DEFA14A | Additional proxy material | Sep 4, 2009 | — |
| DEFA14A | Additional proxy material | Sep 3, 2009 | — |
| DEFA14A | Additional proxy material | Sep 2, 2009 | — |
| DEFA14A | Additional proxy material | Sep 2, 2009 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EMMA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Torrance, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 822370
- Former names
- MYnd Analytics, Inc. (until Jul 12, 2019); CNS RESPONSE, INC. (until Dec 10, 2015); STRATIVATION, INC. (until Mar 1, 2007); SalesTactix, Inc. (until Aug 23, 2005); AGE RESEARCH INC (until Aug 5, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.